Abstract: Inert co-solutes, or excipients, are often included in protein biologic formulations to adjust the tonicity of liquid dosage forms intended for subcutaneous delivery. Despite the low concentration of their use, many of these excipients alter protein-protein interactions such as dimerization and aggregation rates of high concentration monoclonal antibody (mAb) therapeutics to varying extents during long-term refrigerated clinical storage, challenging the formulation scientist to make informed excipient selections at the earliest stages of development when protein supply and time are often limited. The objectives of this study were to better understand how isotonic concentrations of excipients influence the dimerization rates of a model mAb stored at refrigerated and room temperatures and explore protein sparing biophysical methods capable of predicting this dependence. Despite their prevalence of use in the biopharmaceutical industry, methods for assessing conformational stability such differential scanning calorimetry and isothermal equilibrium unfolding showed little predictive power and we highlight some of the assumptions and technical challenges of their use with mAbs. Conversely, measures of colloidal stability of the native-state such as preferential interaction coefficients measured by vapor pressure osmometry and solubility assessed by polyethylene-glycol induced precipitation correlated reasonably well with the mAb dimerization data and are most consistent with the excipients tested minimizing dimerization by interacting favorably with the residues comprising the protein-protein association interface.
Introduction
Aggregation remains one of the principal challenges facing the biopharmaceutical industry in maintaining the physicochemical stability of protein biologics since even minor amounts may adversely affect activity or promote an immunogenic response. [1] [2] [3] This is especially true for liquid dosage forms where a 2-year shelf-life is often desired. 4 To meet this challenge, intrinsic aggregation rates may be lowered by selection and engineering of the protein sequence and extrinsic factors such as solvent conditions or formulation may be optimized. Typical protein formulations designed for this purpose are composed of a buffering agent to maintain pH and any number of co-solutes or excipients, some of which inhibit specific aggregation mechanisms. 4 A number of excipients including sugars, polyols, and amino acids are commonly added to liquid formulations intended for subcutaneous delivery, however, primarily to adjust tonicity. Despite the~250-350 mM isotonic concentration constraint of their use, these excipients often subtly alter dimerization and higher order aggregation rates to varying extents. The primary objective of this study was to understand how isotonic concentrations of these excipients influence the association rates of high concentration protein therapeutics stored at 4 C and 25 C, temperatures encountered during long-term clinical storage and short-term manufacturing, respectively. An immunoglobulin G1 (IgG1) monoclonal antibody (mAb) named "mAb-D" was chosen as a model protein biologic for this purpose since mAbs are currently the fastest growing class of therapeutics and the IgG format is the most commonly used. 5 To simplify our goal, we focused our investigation on only the initial nucleation stage of aggregation to dimer following the canonical Lumry-Eyring model of association (Scheme 1) where a prerequisite for higher order aggregation is the partial unfolding or structural perturbation of the nativestate (N) to an aggregation competent intermediate species (N*) prior to association to dimer (N 2 *). 6, 7 Our general approach consisted of evaluating a handful of biophysical methods to probe the two distinct steps of Scheme 1, partial unfolding and association, for their ability to accurately predict the rank order of the excipient dependence of the rate of mAb-D dimer formation during long-term refrigerated and room temperature storage. Similar strategies testing conformational and colloidal stability have been used in previous reports; however, in most of these instances, the effects of pH and ionic strength were investigated for mAbs stored at elevated temperatures to accelerate higher order aggregation (as opposed to dimer formation) and it remains unclear whether the mechanism or rate limiting step of aggregation under these stressful conditions remain the same at the lower temperatures used for clinical manufacturing and storage. [8] [9] [10] [11] [12] [13] One study that did monitor mAb dimerization at refrigerated temperatures found that measures of colloidal stability such as solubility assessed by ammonium sulfate precipitation and theoretically derived apparent native-state transfer free energies (explained later) were more predictive of the dimerization dependence of model mAbs on excipient type than melting temperatures. 14 Since this study, questions have been raised regarding the use of precipitating salts to estimate protein solubility and concerns for using apparent transfer free energies have been expressed due to some of the assumptions used in their calculation. [15] [16] [17] In the current report, we returned to these approaches, but instead measured solubility by polyethylene-glycol precipitation and experimentally determined a closely related parameter of the nativestate transfer free energy, the protein-excipient preferential interaction coefficient. 18 Our intent is that the results of this report will both help inform the protein scientist which of the two steps of Scheme 1 to focus on during mAb formulation development and identify protein sparring predictive screening methods. This last point is of particular practical interest within the industry and the secondary objective of this report since proteinprotein association reactions are often only manifest at the high mAb concentrations typically required for therapeutic efficacy when administered by low volume (≤ 1 mL) subcutaneous injection, yet formulation studies must be initiated at the earliest stages of development when protein supply and time are limited. Other than accuracy, the predictive screening methods tested in this report were evaluated on the basis of their ease of use, amount of protein required and potential for high-throughput automation.
Results and Discussion
Two sets of mAb-D dimerization data were collected by size exclusion chromatography (SEC) during long-term static storage. Both data sets were conducted at a final mAb-D concentration of 75 mg/mL buffered at pH 7.0 by 10 mM potassium phosphate (KPi). The first monitored the dimerization rates of mAb-D stored at 4 C and 25
C for 17 weeks in the presence of nine different excipients* at final concentrations of 300 mM [ Fig. 1 (A), 1(B)] and the second assessed the dimerization kinetics of mAb-D stored at 4 C for 37 weeks in the presence of 1 M excipient concentrations for Scheme 1. Non-native model of dimerization following the Lumry-Erying framework; N and N* represent the native and partially unfolded intermediate species, respectively. *A broad range of excipients were investigated, including some that living organisms accumulate in response to cellular stresses, but are not typically used in therapeutic formulations such as methylamines. Fig. 1(C) ]. In all cases, the rank order of the excipient dependence of association was generally similar for all of the conditions tested with the exceptions of the temperature and concentration dependence of the glycine and guanidinium hydrochloride (GdnHCl) formulations, respectively. A formulation containing only the 10 mM KPi buffer (KPi) was also included in the second 1 M data set for comparison and demonstrates that all of the excipients tested (with the exception of 1 M glycerol and GdnHCl) limit the rate of mAb-D association to varying extents [ Fig. 1(C) ].
comparison [
The mAb-D high molecular weight (HMW) species was confirmed to be composed of dimer (Fig. S1) and found to be reversible in nature as evident from the initial disassociation of the existing dimer in the concentrated mAb-D stock solution used to prepare the formulations (Fig. 1 ). For this reason the percentages of dimer at the beginning of the study do not exactly overlay for all of the excipients tested since there was a delay between the time of formulation preparation by dilution and analysis by SEC (Fig. 1) . The amounts of dimer present at the final time point of static storage were next correlated with measures of conformational and colloidal stability, since this amount is dependent on the apparent dimerization rate as described in the Supporting Information.
Dimerization dependence on measures of conformational stability
The first methods that we used to predict the rank order of the excipient dependence of mAb-D dimerization ( Fig. 1 ) tested conformational stability, or the difference in free energy between the native and unfolded-states (ΔG N!U ). Several of the excipients chosen for this study are known to increase protein conformational stability by interacting unfavorably with surfaces typically found in the native-state interior such as the hydrophobic side-chains and the peptide backbone in particular. [19] [20] [21] Analogous to their influence on the equilibrium between native and unfolded-states, addition of stabilizing excipients would be expected to decrease the concentration of any partially unfolded intermediate form(s) (N*) and thereby slow the second concentration dependent step of Scheme 1. This strategy has been successfully used for other protein therapeutics including recombinant cytokines stored at physiological temperatures 22 and in the presence of low concentrations of denaturant. 23 
Apparent melting temperatures
Differential scanning microcalorimetry (DSC) was the first biophysical method used to assess the conformational stability of mAb-D since it is perhaps the most widely used method in the industry for this purpose, as it requires relatively little protein (~0.5 mg) and the instrumentation may be largely automated. The drawback with using this and other thermal denaturation methods for determining the conformational stability of mAbs, however, is the lack of thermal unfolding reversibility of their Fab and C H 3 domain, consequently only apparent melting temperatures (T m app ) may be measured. Unfolding thermograms of mAb-D in the presence of the nine excipients used in Figure 1 (plus a few additional excipients explained later) at a concentration of 1 M are shown in Figure S2 . 
Isothermal chemical denaturation experiments
The failure of T m app values to predict the excipient dependence of mAb-D dimerization may stem from the inherent non-linear temperature dependence of ΔG N!U , where a formulation with a greater T m value may not necessarily have a greater ΔG N!U at a lower temperature. 24 This possibility has been better appreciated within the industry in recent years and determination of ΔG N!U at temperatures similar to those used for long-term storage by isothermal equilibrium unfolding experiments have started to gain traction.
To increase the throughput of these traditionally labor intensive and time consuming experiments and make them more amenable for formulation development, liquid handling instruments have been developed within recent years that purport to perform fully automated "hands-off" chemical unfolding experiments. Automation of these systems includes sample preparation, acquisition by monitoring intrinsic fluorescence (FL) and data analysis by fitting the resulting unfolding curves to appropriate models. 25, 26 In light of the increasing importance placed on this biophysical method during formulation development, we sought to determine the ΔG N!U of mAb-D at 25 C by manual GdnHCl titration monitored by intrinsic tryptophan (Trp) FL following overnight incubation. Our resulting curve was well fit to a twostate equilibrium unfolding model (Eq. (S1)) judging by the quality of the fit (reduced χ 2 = 1.4) and the uniform distribution and magnitude of the residuals (Fig. 2) . Moreover, the ΔG N!U (3.7 AE 0.2 kcal mol −1 ) and dependence of ΔG N!U on denaturant concentration or m-value (1.65 AE 0.08 kcal mol
derived from this fit were similar to those reported in the application notes of the commercially available automated systems for other IgG mAbs. 25, 26 Closer inspection of these results and the same unfolding curve monitored by far-ultraviolet circular dichroism [ Fig. S4 (A)], however, raise concerns that may be missed by the formulation scientist or when relying on automated data processing programs that ultimately made the fitted parameters unreliable as detailed further in the Supporting Information.
Estimation of ΔΔG
Due to the inability to experimentally determine the mAb-D ΔG N!U in the presence of the different excipients, we next estimated the mAb-D ΔΔG N!U , the difference of mAb-D conformational stability in the absence (ΔG 0 N!U ) and presence of 1 M excipient concentrations (ΔG 1M N!U ) using Tandford's transfer model. 27, 28 Here the apparent transfer free energies (change in free energy of transferring a protein from water to an excipient solution) of the mAb-D nativestate (ΔG tr,N ) and unfolded-state (ΔG tr,U ) were calculated based on the solvent accessible surface areas (SASAs) of a homology model of mAb-D constructed from its primary sequence (Table S1 ) and the experimentally determined apparent transfer free energies of the amino acid side-chains and model unit of the peptide backbone from water into each of the 1 M excipient solutions provided in the literature. 21, 29, 30 These transfer free energies were then used to calculate the mAb-D ΔΔG N!U by the resulting relationship of the thermodynamic cycle shown in Scheme 2 where
. Further details and assumptions of this "bottom up" approach are given elsewhere by Auton and Bolen who have perfected this method to correctly predict the ΔΔG N!U values for 46 proteins in 9 different 1 M excipient solutions. 31, 32 To our knowledge, this is the first instance that this method has been applied to formulation development and we anticipate that it may prove useful for selecting excipients for instances where conformational stability is a determinate of dimerization or aggregation propensity and accurate measures of ΔG N!U are not possible due to lack of unfolding reversibility or other technical limitations. The predicted ΔΔG N!U values determined for mAb-D using this approach showed excellent correlations to the experimentally determined T m app values of the Fab (Fig. 3 ) and the C H 2 and C H 3 domains (Fig. S6 ). ‡ The adjusted square of the correlation coefficient (R 2 adj ) was used throughout this study to account for data sets with different sample sizes. ‡ The Tm app values for sarcosine, trehalose and urea were also measured by DSC and included in the ΔΔG N!U correlations since transfer free energies of the side-chains and peptide backbone into these 1 M excipients were also available in the literature, 21, 30 transfer free energies into glycine, however, were not.
Similar to the measured T m app values, however, the calculated ΔΔG N!U values also showed no correlation to the amounts of mAb-D dimer formed after 17 weeks of storage at 4 C and 25 C for the 300 mM excipient formulations and after 37 weeks of storage at 4 C for the 1 M excipient formulations (Fig. S7) , further implying that conformational stability is a poor predictor of the excipient dependence of mAb-D dimerization at refrigerated and room temperatures.
Dimerization dependence on colloidal stability
In the same manner that excipients affect the position of the equilibrium between native and unfoldedstates, they also influence the binding free energies between proteins and to other molecules due to differences in their interactions between the associated and disassociated states. 33 Given the apparent lack of correlation between measures of conformational stability and the amounts of mAb-D dimer formed following long-term storage at 4 C and 25 C, we next sought to quantify these excipient-protein interactions and qualitatively rank their effect on the mAb-D intermolecular protein-protein interactions by measuring the mAb-D-excipient preferential interaction coefficients and the excipient dependence of mAb-D solubility, respectively. Since the magnitude of partial unfolding to the putative N* intermediate species (Scheme 1) and degree to which it is populated is unknown, both of these measures of colloidal stability were conducted under native-state conditions with the possible exception of the GdnHCl formulation.
PEG-precipitation
Since mAbs tend to gel at high concentrations, polyethylene glycol (PEG) was used to precipitate mAb-D at 4 C in the presence of the nine excipients used in Figure 1 . Addition of PEG has generally been thought to induce protein precipitation due purely to excluded volume effects 15 The results of the mAb-D precipitated by PEG-3350 in the presence of 1 M concentrations of each of the excipients are shown in Figure 4 . Notwithstanding potential complications due to the PEG-protein and PEG-excipient interactions, all of the excipients tested appear to solubilize mAb-D, or require a greater amount of PEG to induce the same degree of precipitation as the KPi buffer control, in the same general rank order as they decreased the rate of dimerization (Fig. 1) . For a more accurate comparison, the precipitation curves were fit to an empirical sigmoidal equation (Eq. (S3)) and the midpoints derived from these fits were correlated to the amounts of dimer present after 17 weeks of storage at both 4 C and 25 C for the 300 mM excipient formulations [ Fig. 4 (B) and (C)] and to the amounts of dimer present after 37 weeks of storage at 4 C for the 1 M excipient formulations [ Fig. 4(D) ]. The decent correlation of these data sets, as well as the excipients effect on solubility and dimerization relative to the 10 mM KPi buffer control formulation, suggest that the excipients preferentially interact with and hence lower the chemical potential of the mAb-D native-state to various extents depending on the excipient type. This favorable interaction would naturally be expected to shift the equilibrium in the direction of monomer since this species has the greater SASA available for interaction. Although the possibility that dimerization may proceed through an N* species (Scheme 1) cannot be totally ruled out, these correlations suggest that the SASA of the N* species (if present) is similar enough to the native-state that it may be considered belonging to the native-state ensemble rather than a distinct intermediate species. To test some of the underlying assumptions of this simple excipient interaction model, we next measured the excipient-mAb-D preferential interaction coefficients.
Preferential interaction measurements
The preferential interaction coefficient studied in this report (Γ μ3 ) is a measure of the net accumulation or depletion of an excipient near the vicinity of the protein's surface relative to that of the bulk solution. It is defined as the change in excipient molality (m 3 ) with protein molality (m 2 ) at constant temperature, pressure and excipient chemical potential (μ 3 ) and as alluded to previously may be expressed as the mutual perturbations of the excipient and protein chemical potentials by one another according to Eq. (1). [39] [40] [41] Note that the integral of the chemical potential derivative in the numerator of Eq. (1) is equal to the transfer free energy mentioned previously and that subscripts 1, 2, and 3 refer to water, protein, and excipient, respectively following the Scatchard notation 42 :
T, P,m2 ∂μ 3 ∂m3
T, P,m2 ð1Þ
Preferential interaction coefficients have traditionally been measured by equilibrium dialysis/densimetry 43 and more recently by vapor pressure osmometry (VPO) which requires less time and protein. We determined the chemical potential derivatives of Eq. (1) for the nine excipients used in Figure 1 by measuring osmolality by VPO at incrementally increasing excipient concentrations at room temperature in the absence and presence of 75 mg/mL mAb-D following the procedures detailed by Hong et al. 41 and summarized in the methods section. Representative osmolality measurements for sucrose and L-arginine solutions are shown in Figure 5 (A) and (B), respectively; the osmolality data for the remaining excipients are shown in Figure S8 . For clarity, the Γ μ3 derived from the VPO data for five of the excipients used in this study are overlaid in Figure 5 (C) and the remaining Γ μ3 data are shown in Figure S8 . Inspection of the Γ μ3 data indicate that all of the excipients tested, with the exception of GdnHCl, are preferentially excluded from and increase the chemical potential of the mAb-D native-state to varying extents [Figs 5(C) and S8(H)]. In general, a higher percentage of dimer was formed for the more excluded excipients [ Fig. 5(D) and (E)] suggesting that the excipients drive the equilibrium in the direction of greater burial of surface area much as they do to increase conformational stability. This interpretation is ostensibly at odds with the dimerization and PEG solubility data relative to the 10 mM KPi buffer only control formulation that show increases in solubility and decreases in dimerization rates with excipient addition indicative of preferential inclusion (positive Γ μ3 values). These findings, however, are not without precedent, preferentially excluded excipients have been shown in past reports to limit native-state protein-protein interactions including the doubling of bovine pancreatic trypsin inhibitor solubility by the addition of 5% (w/v) glycerol 44 and the increase in the K D interaction parameter for a model mAb with the addition of trehalose. 45 Even arginine, one of the most widely used excipients to enhance native-state protein solubility, has been shown to be preferentially excluded from the surfaces of several proteins including bovine serum albumin, 46 α-chymotrypsinogen, 46 and three model mAbs. 45 We believe that these seemingly conflicting results are consistent considering that only the excipients interaction with the surfaces at the association interface will determine the position of the monomer- dimer equilibrium (assuming no significant structural rearrangements upon association), yet Γ μ3 is a measure of the net excipient interaction with the mAb-D monomer. That is, Γ μ3 should in principle be sufficient to rank order the excipients effectiveness of limiting association only if the weak interacting forces between the excipients and mAb-D are uniformly distributed over the entire surface of the mAb nativestate and representative of the dimerization interface. Based on the literature values of the apparent transfer free energies of the amino acid sidechains and model unit of the peptide backbone into each of the excipients tested in Figures 1 and 5 (Table S1 ). A number of the sidechains on the other hand, particularly the polar and charged sidechains, have favorable apparent transfer free energies into the excipients tested, comprise the bulk of SASA of the native mAb-D monomer and are more or less evenly distributed across the mAb-D surface. We speculate that these residues comprise the protein-protein contact surface(s) and therefore modulate mAb-D association based on their preferential interactions with the excipients tested. The exception to the general correlation between the percentage of dimer and Γ μ 3 is GdnHCl [ Fig. 5 (D) and (E)]. We believe that this may be due to a breakdown of the assumptions mentioned above since this strong denaturant likely causes some degree of structural perturbation of the native-state even at the low concentrations used.
Conclusion
Maximizing conformational stability as a strategy to maintain the shelf-life of therapeutic mAbs makes intuitive sense within the context of Scheme 1, but in practice has often yielded mixed results. 47, 48 This may in part be due to the inherent difficulty in accurately measuring the conformational stability of mAbs given their apparent lack of unfolding reversibility and propensity to aggregate through competing off-pathway reactions during unfolding experiments. It is more likely the case, however, that conformational stability is not a determinate of the association reactions observed for high concentration mAb formulations stored at clinically relevant refrigerated temperatures. In many of the instances where measures of conformational stability such as T m app values have been used successfully to predict the aggregation behavior of mAbs, these mAbs were stored under stressful conditions such as elevated temperatures either at or near the vicinity of their thermal unfolding temperatures 10, 49 and rapidly quenched to native-state conditions so that aggregation could be monitored on much shorter and experimentally accessible minute to hour time-scales. We speculate that rates and structures of the aggregate formed under these conditions, much like the aggregate formed for mAb-D following rapid dilution of denaturing concentrations of GdnHCl (Fig. S5) , may not be representative of the HMW species formed during long-term 4 C storage and may be the cause of the non-Arrhenius kinetics often observed under these conditions. 8, 50 The results of the present study indicate that the mAb-D HMW species is primarily composed of reversible dimer that is likely formed by direct association of native monomer rather than through a structurally altered intermediate species (Scheme 1); whether or not it is on-pathway to higher order aggregate remains to be determined.
Rather than maximizing the conformational stability of mAbs stored at refrigerated temperatures, the results of this study suggest that minimizing the attractive intermolecular interactions of their nativestates may prove to be a more effective strategy for preventing protein-protein association, especially for high concentration formulations due to the excluded volume effects of self-crowding. To this point, an often used approach to minimize mAb aggregation in the biopharmaceutical industry is to formulate them at pH values several units away from their pI at low ionic strength, where conformational stability is lower, but repulsive electrostatic intermolecular interactions are greater provided the surface charge is uniformly distributed. The results of the present study indicate that the type of tonicity modifying excipient should also be taken into careful consideration during formulation development, particularly for those excipients that interact favorably with the polar and charged side-chains, to further minimize protein-protein interactions that could in principle lead to higher order aggregation, phase separation, and increased solution viscosity.
Although our findings indicate that the preferential interaction coefficients may be used as a predictive tool for ranking excipient types, the use of this method does assume that the weak excipient-protein interactions are evenly distributed over the surface of the protein and representative of their interactions at the dimerization interface, which may not always be a valid assumption. In contrast to Γ μ3 but similar to dimerization, the PEG-induced precipitation method involves protein-protein association, presumably at the same points of contact as the dimer formed after long-term storage at refrigerated and room temperatures given the reasonable correlation of their excipient dependence (Fig. 4) . Based on the amount of protein used, the potential for plate-based automation and more straightforward data analysis, we found the PEG precipitation method to be the superior colloidal stability metric for screening different excipients during formulation development. Future work will explore the use of other crowding agents such as dextrans that unlike PEG have been reported to be completely inert and induce precipitation by purely excluded volume effects. 51 
Materials and Methods

Materials
Pharmaceutical quality mAb-D was expressed in Chinese hamster ovary cells, purified, buffer exchanged into 10 mM KPi (pH 7.0) and concentrated to a 150 mg/mL working stock solution. Concentrations were determined by absorbance at 280 nm using an extinction coefficient of 1.6 mLÁmg −1 Ácm −1 . High purity potassium phosphate (monobasic monohydrate and dibasic dihydrate), PEG-3350, glycerol, sucrose, trehalose, sarcosine, sorbitol, L-proline, L-arginine, TMAO, betaine, and glycine were from Sigma-Aldrich (St. Louis, Missouri). Ultra-pure urea and GdnHCl were from MP Biomedicals (Solon, OH). Stock solutions of all the excipients were prepared to a final concentration of 2 M buffered by 10 mM KPi (pH 7.0) and sterile filtered. Prior to filtration, the TMAO and sarcosine stock solutions were further purified by addition of activated carbon and deionized in batch mode by addition of mixed-bed resin from SigmaAldrich (St. Louis, Missouri). A 40% (w/v) PEG-3350 stock solution buffered by 10 mM KPi (pH 7.0) was prepared for the PEG precipitation experiments.
Pharmaceutical stability
The nine 75 mg/mL mAb-D formulations shown in Figure 1 were prepared by dilution from the same 150 mg/mL mAb-D, 10 mM KPi (pH 7.0) stock solution. For the 300 mM and 1 M formulations, 150 μL of the mAb-D stock was added to 150 μL of 600 mM and 1 M excipient solutions (prepared from the 2 M stock solutions), respectively. Following preparation each formulation was filter sterilized and dispensed into sterile 0.5 mL screw-cap microcentrifuge tubes. Formulations were stored at 4 C and 25 C during which time aliquots were collected and analyzed by SEC.
Size-exclusion chromatography SEC was performed on an Agilent 1200 series quaternary pump liquid chromatography system (Agilent, Palo Alto, CA) equipped with a single TosoHaas TSKgel SW3000xl column. Seventy-five μg of mAb-D was injected neat onto the column and eluted isocratically at a flow rate of 0.5 mL/min with a mobile phase that consisted of 100 mM sodium phosphate (pH 7.0) and 150 mM sodium chloride. The absorbance was monitored at 280, 230, and 215 nm.
Differential scanning calorimetry
Differential scanning calorimetry was performed on a TA Instruments NanoDSC (New Castle, DE) using the NanoAnalyze software. Samples were buffered at pH 7.0 with 10 mM KPi at a concentration of 2 mg/mL mAb-D in the presence of the twelve 1 M excipients shown in Figure S2 . Prior to analysis the samples and their corresponding buffers without protein were degassed for 30 min. Samples and buffers were heated from 10 C to 100 C at a rate of 1 CÁmin −1 .
Following acquisition, the corresponding buffers were subtracted from each of the samples and the data were normalized to convert to kcalÁmol −1 Á C −1 . For each thermal unfolding transition, a Gaussian peak was fit and the mode was reported as the T m app .
Isothermal chemical denaturation
Unfolding GdnHCl titration curves were prepared manually by incubating individual 1.0 mL samples consisting of 0.5 mg/mL mAb-D buffered at pH 7.0 with 10 mM KPi in incrementally increasing concentration of GdnHCl from 0 to 7 M for up to 24 h at 25 C. Following 1, 2, 3, 4, 5, 18, and 24 h of incubation 50 μL were withdrawn from the 1.0 mL samples and analyzed at 25 C by monitoring intrinsic Trp FL using a SpectroMax m5e4 plate-reader fluorimeter (Molecular Devices, Sunnydale CA). An excitation wavelength of 295 nm was used and emission spectra were collected from 325 to 380 nm in 1 nm increments for each sample. Following 24 h of incubation the unfolding curve was also analyzed by farultraviolet circular dichroism spectroscopy (far-UV CD). Far-UV CD spectra were collected at 25 C on a Jasco 1500 spectrophotometer (Jasco, Tokyo, Japan) from 260 to 218 nm in 1 nm steps using a bandwidth or 2 nm and path-length of 0.1 cm. The FL and far-UV CD data were fit locally to a two-state unfolding model and normalized to the fraction unfolded as described in the Supporting information.
Homology model of mAb-D for estimation of the native-state SASA
A full homology model of the mAb-D native-state was built using the mAb-D primary sequence and the Antibody Modeler tool in the Molecular Operating Environment (MOE) (Chemical Computing Group, Montreal, Quebec, Canada) in conjunction with an IgG1 crystal structure 1HZH. 52 Energy minimization was performed using the Amber-10:EHT force field. A script was developed that calculated the mAb-D SASA (Table S1) for each amino acid sidechain and backbone using a 1.4 Å probe size equal to the radius of water. 53 The fractional solvent exposure for each type of side-chain and peptide backbone of the native-state was then used together with the apparent group transfer free energies of the amino acid side-chains and model unit of the peptide backbone into the 1 M excipient solutions taken from the literature 21, 29, 30 to determine ΔG tr,N . The same approach was used to determine ΔG tr,U using interpolated upper and lower bound models of the unfolded state SASA. 21, 54 A complete description of these calculations can be found elsewhere. 21, 32 PEG precipitation PEG precipitation experiments were performed by preparing 100 μL solutions consisting of 1 M excipient, 1.0 mg/mL mAb-D, 10 mM KPi (pH 7.0) and incrementally increasing concentrations of PEG-3350 from a 40% (w/v) stock solution. The solutions were placed at 4 C overnight and then centrifuged for 60 min at 25,000 RCF. The amount of mAb-D remaining in the supernatant was then measured by absorbance at 280 nm using an Agilent Cary UV-8454 spectrophotometer (Agilent, Palo Alto, CA). Data were fit to the empirical four-parameter sigmoidal equation (Eq. (S3)).
Vapor pressure osmometry
Osmolality measurements were collected in triplicate on a Wescor Vapro 5520 vapor pressure osmometer (Logan, UT) calibrated using the manufactures 100, 260, and 1000 mOsm standards incorporating the suggestions given by Harries and Rösgen. 33 For each of the excipients tested, two sets of samples buffered at pH 7.0 by 10 mM KPi at incrementally increasing concentrations of excipient were prepared from the 2 M excipient stock solutions, one set contained 75 mg/mL of mAb-D and the other did not.
Prior to determining Γ μ3 by VPO both the non-protein and protein containing sets were converted from the molar to molal concentration scales using the partial molar volumes of the solution components and Eqs. (S4) and (S5). Following conversion, the dependence of osmolality on the molal excipient concentration for both protein and non-protein containing solutions were fit to a quadratic equation fixing the intercepts to the average of 50 osmolality measurements of the buffer solution with and without 75 mg/mL mAb-D, respectively. The chemical potential derivative in the numerator of Eq. (1) was then approximated using Eq. The chemical potential derivative in the denominator of Eq. (1) was then approximated by taking the partial derivative of the non-protein containing solution osmolality according to Eq. (4) as described in further detail by Hong et al. 41 : 
